Dyax Announces Positive DX-2930 and Biomarker Assay Data at ASH

Dyax Corp. DYAX today announced positive results from both preclinical studies of the investigational product DX-2930 and its biomarker assay program for detection of contact system activation of plasma kallikrein (pKal). Data were presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10 in New Orleans, LA.#ASH13 DX-2930 is Dyax's fully human monoclonal antibody inhibitor of pKal. Dyax is developing DX-2930 to be a long-acting prophylactic agent that prevents hereditary angioedema (HAE) attacks. Development plans include a dosage formulation that will permit infrequent self-administration by small volume, subcutaneous injection. DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in healthy See full press release